CD4+CD25+ regulatory T cells and their therapeutic potential

被引:94
|
作者
Randolph, DA [1 ]
Fathman, CG
机构
[1] Stanford Univ, Sch Med, Dept Pediat, Div Neonatol, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA
来源
ANNUAL REVIEW OF MEDICINE | 2006年 / 57卷
关键词
suppressor T cell; type I diabetes; multiple sclerosis; graft-versus-host disease;
D O I
10.1146/annurev.med.57.121304.131337
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The human immune system mounts specific responses to a vast array of antigens. Although this is clearly beneficial in fighting off harmful infections and cancerous cells, the system must be carefully controlled to ensure that normal self-antigens are not targeted. A recently characterized subset of T cells, identified by their cell surface expression of CD4 and CD25, is critical in regulating the function of other immune cells and preventing potentially harmful autoimmune responses. This article reviews what is currently known about these so-called regulatory T cells and discusses the therapeutic potential of these cells to modulate human immune-based diseases.
引用
收藏
页码:381 / 402
页数:22
相关论文
共 50 条
  • [31] The role of CD4+CD25+ regulatory T cells in viral infections
    Vahlenkamp, TW
    Tompkins, MB
    Tompkins, WAF
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2005, 108 (1-2) : 219 - 225
  • [32] The role of CD4+CD25+ regulatory T cells in Leishmania infection
    Belkaid, Y
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (06) : 875 - 885
  • [33] Analysis of the interaction of CD4+CD25+ regulatory T cells with dendritic cells
    Herman, S.
    Bonelli, M.
    Von Dalwigk, K.
    Smolen, J. S.
    Scheinecker, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : A6 - A6
  • [34] A potential side effect of cyclosporin A:: Inhibition of CD4+CD25+ regulatory T cells in mice
    Wang, Hongjun
    Zhao, Liang
    Sun, Zuyue
    Sun, Liguang
    Zhang, Baojun
    Zhao, Yong
    TRANSPLANTATION, 2006, 82 (11) : 1484 - 1492
  • [35] CTLA-4.Ig converts naive CD4+CD25- t cells into CD4+CD25+ regulatory t cells
    Razmara, Marjaneh
    Hilliard, Brendan
    Ziarani, Azadeh K.
    Chen, Youhai H.
    Tykocinski, Mark L.
    INTERNATIONAL IMMUNOLOGY, 2008, 20 (04) : 471 - 483
  • [36] CD4-mediated activation of human CD4+CD25+ regulatory T cells
    Becker, CG
    Wijdenes, J
    Schneider, F
    Knop, J
    Jonuleit, H
    EXPERIMENTAL DERMATOLOGY, 2006, 15 (03) : 204 - 204
  • [37] Epigenetic enzymes are the therapeutic targets for CD4+CD25+/highFoxp3+ regulatory T cells
    Lopez-Pastrana, Jahaira
    Shao, Ying
    Chernaya, Valeria
    Wang, Hong
    Yang, Xiao-Feng
    TRANSLATIONAL RESEARCH, 2015, 165 (01) : 221 - 240
  • [38] CD4+CD25+ regulatory T cells in patients with acute lymphocytic leukemia
    Cao, Xiangshan
    Xie, Xiaobao
    Li, Aaihua
    Qiu, Guoqiang
    BLOOD, 2007, 110 (11) : 38B - 38B
  • [39] Suppression of PPD induced responses by CD4+CD25+ regulatory T cells
    Vukmanovic-Stejic, M
    Taams, LS
    Reed, JR
    Smith, J
    Fletcher, JM
    Dunne, PJ
    Salmon, M
    Rustin, MH
    Akbar, AN
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (01) : 310 - 310
  • [40] How do CD4+CD25+ regulatory T cells control autoimmunity?
    Bluestone, JA
    Tang, QZ
    CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (06) : 638 - 642